HLXA Share Price | MoonLake Immunotherapeutics Stock Analysis & Recommendation

Q: What does MoonLake Immunotherapeutics do?

Overview:MoonLake Immunotherapeutics is a company in the Pharmaceuticals & Biotechnology industry, focused on healthcare, and operates within the small-cap market segment.Financial Snapshot:- Most recent Net Profit: -41 Million (Quarterly Results - Mar 2025)- Market-cap: USD 2,760.75 Million (Small Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -1.00- Return on Equity: -36.27%- Price to Book: 6.77Contact Details:- Address: C/O Cormorant Asset Management, Llp, 200 Clarendon Street Fl 52 BOSTON MA : 02116- Tel: 1 857 7020370

Q: Is MoonLake Immunotherapeutics technically bullish or bearish?

As of 3 October 2025, the technical trend for MoonLake Immunotherapeutics has changed from bullish to mildly bearish. The weekly MACD and KST indicators are both bearish, while the RSI shows a bullish signal. However, the Bollinger Bands and Dow Theory indicate a mildly bearish stance on the weekly timeframe. Daily moving averages are mildly bullish, providing some support. In terms of performance, the stock has seen a significant decline with a 1-month return of -85.43% compared to the S&P 500's 4.15%, and a year-to-date return of -84.01% versus the S&P 500's 14.18%. Overall, the current technical stance is mildly bearish, reflecting weakness across multiple indicators despite some short-term bullish signals.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

296.71 k

Shareholding (Dec 2025)

FII

5.97%

Held by 94 FIIs

DII

75.02%

Held by 23 DIIs

Promoter

3.62%

How big is MoonLake Immunotherapeutics?

22-Jun-2025

As of Jun 18, MoonLake Immunotherapeutics has a market capitalization of 2,760.75 million, categorizing it as a Small Cap company. As of Dec 24, Shareholder's Funds are 446.83 million and Total Assets are 477.93 million, with net sales of 0.00 million and a net profit of -147.83 million for the latest four quarters.

View full answer

What does MoonLake Immunotherapeutics do?

22-Jun-2025

MoonLake Immunotherapeutics is a small-cap biotechnology company focused on healthcare, currently reporting a net profit loss of $41 million and a market cap of $2.76 billion. It has no dividend yield and negative return on equity.

View full answer

Is MoonLake Immunotherapeutics technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, MoonLake Immunotherapeutics shows a mildly bearish trend with bearish MACD and KST indicators, despite a bullish RSI and mildly bullish daily moving averages, reflecting a significant decline of -85.43% over the past month compared to the S&P 500's 4.15%.

View full answer

Compare MoonLake Immunotherapeutics with Similar Stocks

Amicus Therapeutics, Inc.Cerevel Therapeutics Holdings, Inc.ACADIA Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,200 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.06

Return on Equity

-73.97%

Price to Book

4.15

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-63 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

29.92%

6 Months

-66.6%

1 Year

-55.59%

2 Years

-65.35%

3 Years

-14.27%

4 Years

80.74%

5 Years

76.49%

MoonLake Immunotherapeutics for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-240.13%

EBIT to Interest (avg)

-75.25

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

Tax Ratio

0.25%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.15

EV to EBIT

-3.90

EV to EBITDA

-3.96

EV to Capital Employed

-54.78

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-73.97%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Bullish

Bearish

Moving Averages

Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 40 Schemes (15.4%)

Foreign Institutions

Held by 94 Foreign Institutions (5.97%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -35.78% vs -487.34% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-64.50",
          "val2": "-48.30",
          "chgp": "-33.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-63.00",
          "val2": "-46.40",
          "chgp": "-35.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -90.02% vs -174.83% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-242.20",
          "val2": "-141.70",
          "chgp": "-70.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "7.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-230.30",
          "val2": "-121.20",
          "chgp": "-90.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-64.50

-48.30

-33.54%

Interest

2.00

0.00

Exceptional Items

0.00

Consolidate Net Profit

-63.00

-46.40

-35.78%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -35.78% vs -487.34% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-242.20

-141.70

-70.92%

Interest

7.20

0.00

Exceptional Items

0.00

Consolidate Net Profit

-230.30

-121.20

-90.02%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -90.02% vs -174.83% in Dec 2024

All Annual Results

Company CV

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics

Pharmaceuticals & Biotechnology

Helix Acquisition Corp is a blank check company. The Company is incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company is primarily focused on the healthcare industry.

Company Coordinates

Company Details

C/O Cormorant Asset Management, Llp, 200 Clarendon Street Fl 52 BOSTON MA : 02116

Tel: 1 857 7020370

Registrar Details